Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Plos One|January 24, 2013
Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study)Ann K Sullivan, Dorthe Raben, Joanne Reekie, et al.
The Journal of Infectious Diseases|February 16, 2010
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infectionDavid A Cooper, Jayvant Heera, James Goodrich, et al.
Scientific Reports|April 15, 2016
Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in limited recovery in latently HIV infected T-cell lineAmit Kumar, Wasim Abbas, Laurence Colin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 30, 2007
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005Bruno Hoen, David A Cooper, Fiona C Lampe, et al.
AIDS Research and Human Retroviruses|June 12, 2008
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccineSanjay Mehendale, Jan van Lunzen, Nathan Clumeck, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 30, 2004
Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring systemRainer Ziermann, Linda Celis, Inge Derdelinckx, et al.
Plos Pathogens|July 31, 2015
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene ExpressionGilles Darcis, Anna Kula, Sophie Bouchat, et al.
Plos One|July 1, 2009
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infectionSophie Reuse, Miriam Calao, Kabamba Kabeya, et al.
AIDS (London, England)|April 18, 2003
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsRemko van Leeuwen, Christine Katlama, Robert L Murphy, et al.
Human Vaccines & Immunotherapeutics|May 29, 2012
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse eventsClaudia Schmidt, Carol Smith, Burc Barin, et al.
Pageof 7